Posterior Segment Neoplasm Bibliography

COMS

Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings, COMS report no. 18. Arch Ophthalmol. 2001;119(7):969-982. doi:10.1001/archopht.119.7.969.

Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, V: twelve-year mortality rates and prognostic factors, COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684-1693. doi:10.1001/archopht.124.12.1684.

Diener-West M, Reynolds SM, Agugliaro DJ, et al; Collaborative Ocular Melanoma Study Group Report 23. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group report 23. J Clin Oncol. 2004;22(12):2438-2444. doi:10.1200/JCO.2004.08.194.

Hawkins BS; Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors, COMS report number 24. Am J Ophthalmol. 2004;138(6):936-951. doi:10.1016/j.ajo.2004.07.006.

Margo CE. The Collaborative Ocular Melanoma Study: an overview. Cancer Control. 2004;11(5):304-309. doi:10.1177/107327480401100504.

Melanoma Diagnosis and Management

Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2021;385:1196–1206.

Bechrakis NE, Petousis V, Willerding G, et al. Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate [published online December 3, 2009]. Br J Ophthalmol. 2010;94(4):460-466. doi:10.1136/bjo.2009.162487.

Finger PT, Chin KJ, Yu GP; Palladium-103 for Choroidal Melanoma Study Group. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma [published online February 6, 2010]. Am J Ophthalmol. 2010;149(4):608-615. doi:10.1016/j.ajo.2009.11.006.

Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology. 1999;106(8):1571-1577. doi:10.1016/S0161-6420(99)90455-4.

Hawkins BS; Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, IV: ten-year mortality findings and prognostic factors, COMS report number 24. Am J Ophthalmol. 2004;138(6):936-951. doi:10.1016/j.ajo.2004.07.006.

Jouhi S, Jager MJ, de Geus SJR, Desjardins L, Eide NA, Grange JD, Kiilgaard JF, Seregard S, Midena E, Parrozzani R, Caujolle JP, Rospond-Kubiak I, Kivelä TT. The Small Fatal Choroidal Melanoma Study. A Survey by the European Ophthalmic Oncology Group. Am J Ophthalmol. 2019 Jun;202:100-108. doi: 10.1016/j.ajo.2019.01.031. Epub 2019 Feb 15. PMID: 30772347.

Murray TG, Gold AS, Markoe AM, et al. Spectral-domain optical coherence tomography evaluation of choroidal melanoma and nevus fine-needle aspiration biopsy incision sites. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):165-168. doi:10.3928/23258160-20140306-11.

Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219-1228. doi:10.1001/archopht.118.9.1219.

Shields CL, Dalvin LA, Ancona-Lezama D, et al. CHOROIDAL NEVUS IMAGING FEATURES IN 3,806 CASES AND RISK FACTORS FOR TRANSFORMATION INTO MELANOMA IN 2,355 CASES: The 2020 Taylor R. Smith and Victor T. Curtin Lecture. Retina (Philadelphia, Pa.). 2019 Oct;39(10):1840-1851. DOI: 10.1097/iae.0000000000002440.

Shields CL, Dalvin LA, Yu MD, Ancona-Lezama D, Di Nicola M, Williams BK, Lucio-Alvarez JA, Ang SM, Maloney SM, Welch RJ, Shields JA. CHOROIDAL NEVUS TRANSFORMATION INTO MELANOMA PER MILLIMETER INCREMENT IN THICKNESS USING MULTIMODAL IMAGING IN 2355 CASES: The 2019 Wendell L. Hughes Lecture. Retina. 2019 Oct;39(10):1852-1860. doi: 10.1097/IAE.0000000000002508. PMID: 30883534.

Straatsma BR, Diener-West M, Caldwell R, Engstrom RE; Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol. 2003;136(1):47-54. doi:10.1016/S0002-9394(02)02270-5.

Melanoma Genetics

Harbour JW, Correa ZM, Schefler AC, Mruthyunjaya P, Materin MA, Aaberg TA Jr, Skalet AH, Reichstein DA, Weis E, Kim IK, Fuller TS, Demirci H, Piggott KD, Williams BK, Shildkrot E, Capone A Jr, Oliver SC, Walter SD, Mason J 3rd, Char DH, Altaweel M, Wells JR, Duker JS, Hovland PG, Gombos DS, Tsai T, Javid C, Marr BP, Gao A, Decatur CL, Dollar JJ, Kurtenbach S, Zhang S. 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). J Clin Oncol. 2024 Oct;42(28):3319-3329. doi: 10.1200/JCO.24.00447. Epub 2024 Jul 25. PMID: 39052972; PMCID: PMC11421563.

Maerker DA, Zeschnigk M, Nelles J, et al. BAP1 germline mutation in two first grade family members with uveal melanoma. Br J Ophthalmol. 2014;98(2):224-227. doi:10.1136/bjophthalmol-2013-303814.

Midena E, Bonaldi L, Parrozzani R, Radin PP, Boccassini B, Vujosevic S. In vivo monosomy 3 detection of posterior uveal melanoma: 3-year follow-up [published online October 13, 2007]. Graefes Arch Clin Exp Ophthalmol. 2008;246(4):609-614. doi:10.1007/s00417-007-0692-4.

Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families [published online April 24, 2012]. PLoS One. 2012;7(4):e35295. doi:10.1371/journal.pone.0035295.

Onken MD, Worley LA, Char DH, et al. Collaborative Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma [published online April 21, 2012]. Ophthalmology. 2012;119(8):1596-1603. doi:10.1016/j.ophtha.2012.02.017.

Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma [published online August 21, 2008]. Invest Ophthalmol Vis Sci. 2008;49(12):5230-5234. doi:10.1167/iovs.08-2145.

Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19(1):22-28. doi:10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2.

Review

Shields CL, Kaliki S, Furuta M, et al. American Joint Committee on Cancer Classification of Uveal Melanoma (anatomic stage) predicts prognosis in 7,731 patients: The 2013 Zimmerman Lecture [published online March 24, 2015]. Ophthalmology. 2015;122(6):1180-1186. doi:10.1016/j.ophtha.2015.01.026.

Shields JA, Shields CL. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture [published online October 14, 2014]. Ophthalmology. 2015;122(2):414-428. doi:10.1016/j.ophtha.2014.08.046.

Lymphoma

Brown NA, Balikov DA, Boyer D, Betz BL, Behdad A, Sassalos TM, Demirci H, Rao RC. Cell-free DNA from Aqueous and Dilute Vitreous Improves Detection of Vitreoretinal Lymphoma. Ophthalmol Retina. 2024 Dec 12:S2468-6530(24)00586-4. doi: 10.1016/j.oret.2024.12.010. Epub ahead of print. PMID: 39672304.

Yang X, Dalvin LA, Lim LS, Mashayekhi A, Shields JA, Shields CL. Ultra-low-dose (boom-boom) radiotherapy for choroidal lymphoma in three consecutive cases. Eur J Ophthalmol. 2021 Mar;31(2):NP91-NP96. doi: 10.1177/1120672119888985. Epub 2019 Nov 24. PMID: 31760781.

Other

Henry Wiley, Hanna R. Coleman, Eric Jonasch, Ramaprasad Srinivasan, Frede Donskov, Anders Kruse, Jodi K. Maranchie, Jay Chhablani, Tobias Else, Hakan Demirci, Benjamin L. Maughan, Mary Elizabeth Hartnett, Rodolfo F. Perini, Eric K. Park, Emily Y Chew; Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease. Invest. Ophthalmol. Vis. Sci. 2021;62(8):32.

Arepalli S, Kaliki S, Shields CL. Choroidal metastases: origin, features, and therapy. Indian J Ophthalmol. 2015 Feb;63(2):122-7. doi: 10.4103/0301-4738.154380. PMID: 25827542; PMCID: PMC4399120.

Bansal AS, Bianciotto CG, Maguire JI, Regillo CD, Shields JA, Shields CL. Safety of pars plana vitrectomy in eyes with plaque-irradiated posterior uveal melanoma. Arch Ophthalmol. 2012 Oct;130(10):1285-90. doi: 10.1001/archophthalmol.2012.2391. PMID: 23044941.

Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018 Jun;38(6):1063-1078. doi: 10.1097/IAE.0000000000002181. PMID: 29689030.

Transpupillary Thermotherapy

Mashayekhi A, Shields CL, Rishi P, et al. Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control [published online November 14,014]. Ophthalmology. 2015;122(3):600-609. doi:10.1016/j.ophtha.2014.09.029.

Updated March 2025